Study to evaluate the long-term safety, tolerability and efficacy of bimekizumab in patients with chronic plaque psoriasis.

Registry ID

EUCTR2016-001892-57

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

UCB Biopharma SPRL

Start date

2016-11-08

Completion date

2018-09-25

Last update

2026-08-16

Conditions

• Chronic plaque psoriasis

Summary

Assess the long-term safety and tolerability of bimekizumab.

Locations

• , , Czechia
• , , Poland
• , , Hungary

View on source registry